All the news Showing 10 of 135 articles from: Interferon-free regimensGet an RSS feed of these articles Show All news infohep newsEditors' picks from other sources U.S. FDA Approves Two Supplemental Indications for Harvoni® in Chronic Hepatitis C Patients With Advanced Liver Disease Gilead press release / 17 February 2016 Fair Pricing Coalition Recognizes Merck’s Lower Price for Curative Hepatitis C Treatment, Calls for Manufacturers to Reduce Excessive Prices and Increase Patient Assistance Fair Pricing Coalition / 08 February 2016 Merck Throws a Wrench in Drug Pricing Bloomberg / 01 February 2016 Zepatier for hepatitis C approved in Canada CATIE / 01 February 2016 Merck Receives FDA Approval of ZEPATIER™ (elbasvir and grazoprevir) for the Treatment of Chronic Hepatitis C Virus Genotype 1 or 4 Infection in Adults Merck press release / 29 January 2016 Gilead Announces U.S. FDA Priority Review Designation for Sofosbuvir/Velpatasvir for Treatment of All Genotypes of Chronic Hepatitis C Infection Gilead press release / 05 January 2016 AbbVie Announces FDA Acceptance of New Drug Application for a Once-Daily Formulation of VIEKIRA PAK® AbbVie press release / 02 December 2015 Gilead Announces SVR12 Rates from Four Phase 3 Studies Evaluating a Once-Daily, Fixed-Dose Combination of Sofosbuvir (SOF) and Velpatasvir (VEL) (GS-5816) for the Treatment of All Six Hepatitis C Genotypes Gilead press release / 21 September 2015 Updated Label for Daklinza (daclatasvir) for the 12-week Treatment of Non-cirrhotic Patients with Chronic Hepatitis C Genotype 3 Approved by the European Commission Bristol-Myers Squibb press release / 15 September 2015 Ongoing Real World Study Reports High Sustained Viral Response Rates with VIEKIRAX® + EXVIERA® in Genotype 1 Hepatitis C Patients AbbVie press release / 14 September 2015 ← Prev12345...14Next → Other pages in this section Latest news All the news Hepatitis A Hepatitis B Hepatitis C Hepatitis D Hepatitis E Coronavirus NAFLD Treatment for hepatocellular carcinoma Transmission, epidemiology and prevention Health services, policy and advocacy Social issues Conference news Email bulletin archive